You just read:

VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis (ALS)

News provided by

VM BioPharma

17 May, 2016, 11:00 ET